Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

mon share, compared to net income of $0.2 million, or $0.02 per diluted common share, in the second quarter of 2010. Net loss for the six months ended June 30, 2011 increased to $9.6 million, or $0.99 per diluted common share, compared to net loss of $2.9 million, or $0.45 per diluted common share, in the same period of 2010.
  • An income tax recovery of $3.0 million was recorded in the second quarter of 2010, in relation to the Collaboration Agreement with Teva.
  • We had $75.4 million in cash, cash equivalents and short-term investments as of June 30, 2011, compared to $85.1 million as of December 31, 2010. As at August 1, 2011, we had 9,725,489 shares outstanding.

  • Conference Call DetailsOncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, August 4, 2011, to provide a business update and discuss the second quarter financial results. A live event will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.oncogenex.com . Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

    About OncoGenex PharmaceuticalsOncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug c
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... -- Aspire Technology Partners (Aspire) announced today that it has ... designation recognizes Aspire for delivering outstanding customer service to customers ... "Achieving exceptional results for our customers is core ... and CEO of Aspire. "We are pleased Cisco has recognized ... and are proud to be part of the Cisco channel." ...
    (Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
    (Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
    Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3
    ... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
    ... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
    Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
    (Date:8/1/2014)... Oxford Gene Technology (OGT) is a ... include CytoSure heamatological cancer +SNP Array, CytoSure ISCA ... array, CytoSure ISCA sample tracking spike-ins and CytoSure ... as targeted sequencing services, SureSeq Solid Tumour Panel ... analysis, cytosure services and aCGH for CNV analysis. ...
    (Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
    (Date:8/1/2014)... LA The Health Resources and Services Administration ... Orleans School of Nursing an Advanced Nursing Education ... years. The funding will support training interprofessional teams ... for military veterans and diverse populations with behavioral ... DNP, CRNA, LSUHSC Nurse Anesthesia Program Director and ...
    (Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... "Des" O,Neill, MA, MD, FRCPI, AGSF, FRCP(Glasg), FRCP, FRCP(Edin), ... the 2014 recipient of the Joseph T. Freeman Award. ... geriatrics and is awarded to a prominent physician in ... practice who is a member of the Society,s ...
    (Date:8/1/2014)... 01, 2014 Lifeinsurancenomedicalexam.info has released ... insurance for clients who have high cholesterol levels. ... find and qualify for no medical exam life insurance. ... any background medical check-ups. , Since there are no ... level will qualify in just a few minutes. However, ...
    Breaking Medicine News(10 mins):Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:O'Neill to receive GSA's 2014 Joseph T. Freeman Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
    ... in French . A team of ... have discovered a type of "cellular bilingualism" a ... different methods of communication to exchange information. "Our work ... function of dopaminergic, serotonergic and cholinergic neurons in diseases ...
    ... By Alan Mozes HealthDay Reporter , THURSDAY, March ... therapy may have gotten a little closer to reality, with ... hearts that were dangerously swollen after heart attacks. The ... bone marrow, then injecting them into the patient,s damaged heart. ...
    ... , WEDNESDAY, March 16 (HealthDay News) -- ... children participating in their school,s band, a new study ... high school band and found they were heavily contaminated ... which are associated with minor to serious infections and ...
    ... for the first time that stem cells injected into ... improved function to injured heart areas, according to a ... the American Heart Association . , Researchers said that ... findings are promising for the more than five million ...
    ... increasing frequency, parents of children with autism spectrum disorder ... their children wander or unexpectedly run away. One mother ... wandered away from her home, despite efforts to lock ... this problem, Autism Speaks, the world,s largest autism science ...
    ... -- Many American children who qualify for public health ... parents are confused about enrollment and eligibility, new research ... low-income households in Oregon and found that about 23 ... were not enrolled in the Oregon Health Plan (OHP), ...
    Cached Medicine News:Health News:'Bilingual' neurons may reveal the secrets of brain disease 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 3Health News:Heart damage improves, reverses after stem cell injections in a preliminary human trial 2Health News:Autism Speaks supports new diagnostic code for individuals with autism with history of wandering 2Health News:Parents Often Confused About Kids' Health Coverage 2
    Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
    Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
    ... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
    ... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
    Medicine Products: